ARVN

Arvinas develops proteolysis-targeting chimera (PROTAC) protein degrader therapies representing a novel approach to treating cancer and other diseases by selectively eliminating disease-causing proteins rather than merely inhibiting their function. Headquartered in New Haven, Connecticut, Arvinas pioneered the PROTAC technology platform which uses small molecules that bind simultaneously to a target protein and cellular protein degradation machinery, triggering destruction of the target protein through the body's natural protein disposal system. The company's lead clinical candidates include ARV-471, an orally bioavailable estrogen receptor degrader in Phase 3 trials for metastatic breast cancer, and ARV-766, an androgen receptor degrader in Phase 2 development for prostate cancer. Arvinas's PROTAC approach potentially offers advantages over traditional small molecule inhibitors including ability to target previously "undruggable" proteins lacking active binding sites, improved potency through catalytic recycling allowing single PROTAC molecules to degrade multiple target proteins, and reduced resistance development. The company established significant partnerships including a $650 million collaboration with Pfizer co-developing ARV-471 and sharing development costs and commercialization rights, plus a Bayer collaboration focused on PROTAC degraders for oncology and non-oncology targets. Arvinas completed its initial public offering in September 2018 and employs approximately 350 people conducting drug discovery, clinical development, and manufacturing process development supporting its growing pipeline of protein degrader therapeutics.